Additionally, WAT ATGL is the first identified biosynthetic enzyme of mammalian fatty acid esters of hydroxy fatty acids (FAHFAs) some of which have anti-diabetic actions further highlighting FoxO1 and ATGL as therapeutic targets for T2D treatment (141). The gene discussed is FOXO1; the disease is type 2 diabetes mellitus.